Aerie Ready for Data Release Later This Year

Aerie Ready for Data Release Later This Year - OIS@ASCRS 2016

COO Tom Mitro visits with OISTV to give an update on Aerie’s clinical trial progress. 00:25 – Update on Rhopressa. What’s the good news? 00:39 – Data due on Mercury1 00:57 – Aerie will deliver some scoops at OIS@AAO 01:10 – What’s the goal for ASCRS? 01:25 – Is it challenging to recruit patients for…

Read More

Ocular Therapeutix Waiting for Word from FDA

Ocular Therapeutix expects to hear from the FDA on its PDUFA date of July 24, 2016, on its new drug application for DEXTENZA, its sustained-release dexamethasone intracanalicular depot drug product candidate for treatment of postoperative pain, President and CEO Amar Sawhney, PhD, told the audience at OIS@ASCRS during the Ophthalmology Innovation Showcase. DEXTENZA would be…

Read More

Aerie Looks for Rhopressa NDA in Q3

Aerie Pharmaceuticals has completed all patient visits in two Phase III clinical trials of the Rho kinase inhibitor Rhopressa (netarsudil) 0.02% for treatment of glaucoma and expects to file a New Drug Application with the FDA in the third quarter of this year, president and COO Tom Mitro reported at OIS@ASCRS 2016. Rhopressa lowers intraocular…

Read More

Dempsey on Building the Shire Brand in Ophthalmology

Dempsey on Building the Shire Brand in Ophthalmology - OIS Podcast - Eye On Innovation

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 087″] Robert Dempsey, vice president of ophthalmics at Shire, was charged with building a brand in ophthalmology with no new drugs. Two years later, Shire has – in the words of one physician – one of “the best kept secrets” in eye care. Dempsey explains how Shire came to build something…

Read More

Encore Vision Reports Positive Phase I/II Results

Results from a Phase I/Phase II study of EV06 ophthalmic solution for the treatment of presbyopia show “it works to restore bilateral near vision. It is safe and well-tolerated,” said president and CEO Bill Burns. Encore Vision has just come off a round of successful capital financing that should see it through the next phase…

Read More

OISPodcast@ASCRS – Meury: Why Allergan Won’t Miss a Beat in Building Ophthalmology Franchise

OISPodcast@ASCRS - Meury: Why Allergan Won’t Miss a Beat in Building Ophthalmology Franchise - OIS Podcast - Eye On Innovation

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 086″] Deals sometime collapse, but they usually don’t get hit with a smart bomb from the Department of Treasury. Allergan, newly single following the break up with Pfizer, is looking to build a business in ophthalmology. Bill Meury, the newly named chief commercial officer of Allergan, talks about the non-Pfizer deal,…

Read More

Masters of The Universe

The day concluded with the Masters of the Universe panel where AcuFocus executive chairman Jim Mazzo led a discussion between Link and executives from Abbott Medical Optics, Alcon, Allergan, Bausch & Lomb, Carl Zeiss Meditec, and Johnson & Johnson Vision Care. Mazzo introduced the panel – and the notion of industry consolidation – with a…

Read More

Graybug Vision – Making Big Moves

Graybug Vision – Flush with Cash – Is Making Big Moves to Change Its Approach to Finding New Treatments for Wet AMD and Other Eye Disease - OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 084″] Graybug interim CEO Jeff Cleland shares details on the company’s $44.5 million Series B. Cleland gives a report on investor appetite for ophthalmology companies. He also explains how the firm would use the capital to shift its approach from a drug delivery platform technology company to a drug maker. Ten…

Read More

Sun Ophthalmics Looks to Build a Brand-New Business in the US

Sun Ophthalmics Looks to Build a Brand-new Business in the US - OIS Podcast

Sun Pharma, the fifth largest pharma company in the US, targeted ophthalmology as one of the first planks in its new branded pharma business. Hear ophthalmology veteran Jerry St. Peter explain how Sun Ophthalmics hopes to build a new team in ophthalmology. Ten Top Topics in this OIS Podcast: What are the origins of Sun…

Read More

Eye on Five – April Edition

OIS - Eye on Five

FDA Approves Avedro Corneal Collagen Cross-linking Platform The US Food and Drug Administration finally gave a green light to Avedro Inc. for its KXL System, a corneal collagen cross-linking platform for the treatment of progressive keratoconus. An FDA joint panel recommended approval in February last year, but a month later the agency denied approval, asking…

Read More

Avedro’s Long Wait for FDA Approval is Over

Avedro’s Long Wait for FDA Approval Is Over - OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 082″] The FDA approved Avedro’s New Drug Application for its riboflavin ophthalmic solution/KXL System (corneal cross-linking for the treatment of keratoconus and corneal ectasia following refractive surgery). OIS Co-chair Gil Kliman, an investor in Avedro, lays out the company’s next plans. 10 Top Topics in this OIS Podcast: Can you give…

Read More